Interferon-beta 1b ( DrugBank: Interferon-beta )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎5

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-005450-30-AT
(EUCTR)
08/01/201411/11/2013Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapyAnti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - ABIRISK Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Avonex
INN or Proposed INN: Interferon-beta 1a
Other descriptive name: INTERFERON BETA-1A
Trade Name: Rebif
INN or Proposed INN: Interferon-beta 1a
Other descriptive name: INTERFERON BETA-1A
Trade Name: Betaferon
INN or Proposed INN: Interferon-beta 1b
Other descriptive name: INTERFERON BETA-1B
Trade Name: Extavia
INN or Proposed INN: Interferon-beta 1b
Other descriptive name: INTERFERON BETA-1B
Trade Name: Rebif
INN or Proposed INN: Interferon-beta 1a
Other descriptive name: INTERFERON BETA-1A
Trade Name: Rebif
INN or Proposed INN: Interferon-beta 1a
Other descriptive name: INTERFERON BETA-1A
Medizinische Universität InnsbruckNULLNot RecruitingFemale: yes
Male: yes
100Phase 4Austria;Sweden
2NCT00490906
(ClinicalTrials.gov)
June 200721/6/2007Comparison of Bone Effects With Copaxone and Interferon in Multiple SclerosisComparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot StudyMultiple Sclerosis;Low Bone DensityDrug: Copaxone;Drug: Interferon-beta 1a;Drug: Interferon-beta 1bNancy Hammond, MDKansas City Area Life Sciences Institute, Inc.Completed18 YearsN/AFemale60N/AUnited States
3NCT00468182
(ClinicalTrials.gov)
April 200730/4/2007Modulation of Plasmacytoid Dendritic Cell Function in Multiple SclerosisModulation of Plasmacytoid Dendritic Cell Function in Multiple SclerosisMultiple SclerosisDrug: Interferon-beta 1b (Betaseron)Rutgers, The State University of New JerseyBayerCompleted18 Years60 YearsBoth24United States
4NCT01111656
(ClinicalTrials.gov)
March 200715/3/2010Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bSWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)Relapsing-remitting Multiple SclerosisDrug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin groupUniversity Hospital Inselspital, BerneViollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, SwitzerlandCompleted18 Years67 YearsBoth28Phase 2Switzerland
5NCT00942591
(ClinicalTrials.gov)
May 200517/7/2009Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1bEfficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.Multiple SclerosisDrug: Interferon beta 1b;Drug: AtorvastatinUniversity Hospital Inselspital, BerneCRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 BaselCompleted18 Years55 YearsBoth77Phase 2Switzerland